Marcain Heavy 0.5%

Quick links

Choose a section

Quick links to important sections

Advertisements

Marcain Heavy 0.5%

Advertisements
Advertisements

Method of action: Anesthetic, Local Anesthetic

Advertisements

Overview of Marcain Heavy 0.5%

What is Marcain Heavy 0.5%?

Marcain Heavy 0.5% is a sterile, clear solution specifically formulated for spinal anesthesia. It belongs to a group of medicines known as local anesthetics of the amide type. The solution contains the active ingredient bupivacaine hydrochloride in a concentration of 5 mg/mL, combined with glucose (sugar) to modify its density.

Composition and Mechanism

The medication is composed of:

  • Bupivacaine Hydrochloride: The primary anesthetic agent that works by temporarily blocking the transmission of nerve impulses in the spinal cord. This prevents the sensation of pain from reaching the brain and causes temporary muscle relaxation in the affected area.
  • Glucose (80 mg/mL): This addition makes the solution 'heavy' (hyperbaric) compared to the natural cerebrospinal fluid. The increased density allows the movement and distribution of the anesthetic within the spinal canal to be influenced by gravity and the patient's physical positioning.

Clinical Application

Marcain Heavy 0.5% is utilized for providing regional anesthesia during surgical procedures. It is injected into the subarachnoid space (the area surrounding the spinal cord) to produce a predictable and localized loss of sensation. This type of anesthesia is typically used for surgeries involving the lower abdomen, pelvis, and lower extremities, including orthopedic procedures and certain obstetric or urological surgeries.

Regulatory References

  1. Bupivacaine - StatPearls - NCBI Bookshelf - NIH
Advertisements

What side effects are possible with Marcain Heavy 0.5%?

Possible Side Effects and Safety Information

The safety profile for Marcain Heavy 0.5% (bupivacaine spinal injection) is structured by regulatory authorities based on the frequency of occurrence and the body system affected. Many documented effects are difficult to distinguish from the expected physiological consequences of the spinal nerve block itself, such as changes in blood pressure.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on their rate of occurrence, according to regulatory standards:

  • Very Common (Affects more than 1 in 10 people): Low blood pressure (Hypotension), slow heart rate (Bradycardia), and Nausea.
  • Common (Affects 1 in 100 to 1 in 10 people): High blood pressure (Hypertension), abnormal skin sensations (Paresthesia), Postdural puncture headache, Dizziness, Vomiting, and difficulty passing urine (Urinary retention).
  • Uncommon (Affects 1 in 1,000 to 1 in 100 people): Muscle weakness (Paresis), convulsions, loss of consciousness, tremor, and slurred speech (Dysarthria).
  • Rare (Affects less than 1 in 1,000 people): Cardiac arrest, severe systemic allergic reactions (Anaphylactic shock), total unintentional spinal block, paralysis, and severe breathing difficulty (Respiratory depression).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight serious adverse reactions that are rare but clinically critical, including Cardiac Arrest, Total Unintentional Spinal Block, and Anaphylactic Shock. The medication is restricted for use in individuals with known hypersensitivity to bupivacaine or any other local anesthetic of the amide-type. Early signs of potential systemic toxicity may include restlessness, dizziness, or visual disturbances.

Population-Specific Safety Notes

Specific safety considerations are noted for certain populations. Older adults and patients in the late stages of pregnancy have a documented increased risk for high or total spinal blockade. Caution is also noted for patients with severe hepatic impairment due to the liver's role in processing this type of anesthetic.

Advertisements

Overdose and Emergency Response

Overdose for Bupivacaine hydrochloride (the active ingredient in Marcain Heavy 0.5%) is described as systemic toxicity, primarily affecting the Central Nervous System (CNS) and Cardiovascular System (CVS). Initial signs of systemic toxicity often include Tinnitus, Blurred vision, and Perioral Paresthesia (numbness around the mouth), progressing to Tremors, Confusion, and involuntary muscular Twitching.

Immediate Medical Attention is required upon the appearance of any signs of toxicity, and the injection must be immediately stopped. Failure to properly manage these initial signs without delay is documented in regulatory labeling to lead to severe outcomes. The most serious outcomes cited in official documents include escalating CNS effects like Convulsions and Coma, leading to Respiratory Arrest. Cardiovascular collapse may manifest as severe Hypotension, Ventricular Fibrillation, and potentially fatal Cardiac Arrest.

No specific antidote is known for Bupivacaine toxicity; consequently, management relies on immediate, specialized supportive measures. This involves securing a Patent Airway, administering 100% Oxygen, and continuous monitoring of Vital Signs and State of Consciousness in a setting where resuscitative equipment is immediately available. Increased risk or severity of toxicity is noted for Elderly Patients and individuals with severe Hepatic or Renal disease.

Advertisements

Therapeutic Uses of Marcain Heavy 0.5%

What Marcain Heavy 0.5% Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed to address acute, intense pain related to invasive procedures. This formulation is generally used for conditions presenting with acute episodes and symptoms related to physical discomfort that require a profound regional block.

It provides supportive relief in clinical settings marked by temporary physiological imbalance, specifically for major surgical procedures of the lower body, including the abdomen, pelvis, and lower limbs, as well as for obstetrical procedures like Caesarean sections. The medication helps address symptom clusters that may become intense or disruptive, such as sensation and temporary motor function in the targeted area.

Profound Anesthesia for Lower Body Surgery

This medication is commonly used to help with the symptoms related to physical discomfort that arises from major surgical procedures. It provides a profound, controlled sensory block, which contributes to improved comfort during periods of heightened symptoms by helping ease the overall symptom burden during the intervention.


Quick Fact: Relief for Acute Procedural Pain

Therapeutic Focus Benefit to the Patient
Sensation Block Contributes to improved comfort during periods of acute pain
Motor Block Assists with maintaining functional stability in the targeted area
Context Applied across conditions presenting with acute episodes of pain

Regulatory References

  1. Medsafe Datasheet for Marcain Spinal 0.5% Heavy
Advertisements

Eligibility and Restrictions for Use

Approved and Restricted Populations

Marcain Heavy 0.5% is intended for use in the adult population undergoing lower-body and obstetrical surgical procedures. Regulatory documentation strictly defines populations who must not use the medicine and those who require special caution.

Contraindications (Must Not Use)

The medicine is contraindicated in populations with absolute prohibitions related to the drug or the spinal administration route:

  • Known hypersensitivity to bupivacaine or any amide-type local anesthetic.
  • Severe systemic instability, including cardiogenic or hypovolaemic shock, severe hemorrhage, or uncorrected coagulation disorders.
  • Active local or systemic infection (septicaemia, infection at the puncture site).
  • Active CNS or spinal column diseases, such as meningitis, spinal tumours, or severe spinal stenosis.

Age and Conditional Restrictions

  • Pediatric Use: Use is not recommended for patients younger than 12 years, as safety and efficacy for spinal administration have not been established.
  • Organ Function: Special attention and monitoring are required for patients with severe hepatic or renal dysfunction.
  • Geriatric Use: Geriatric patients (65 years and over) require careful monitoring due to an increased risk of hypotension.
  • Pregnancy: The 0.5% concentration is generally acceptable for use during childbirth (e.g., Caesarean section).
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Marcain Heavy 0.5% defines interactions based on the risk of additive systemic toxicity and documented pharmacokinetic clearance constraints.

Pharmacodynamic Interaction Risks

The systemic toxic effects are additive when the medicine is co-administered with other local anesthetic agents of the amide-type. This interaction requires monitoring for neurologic and cardiovascular effects due to the potential for cumulative toxicity.

Additionally, exposure to bupivacaine alongside certain drugs associated with methemoglobinemia increases the patient’s risk of developing that condition. This category includes, but is not limited to, nitrates, nitrites, certain antineoplastic agents, and sulfonamide antibiotics.

Clearance and Population Constraints

The drug's clearance profile establishes constraints based on organ function. Severe hepatic disease may result in slower drug clearance due to reduced metabolic capacity in the liver, increasing the potential for toxic plasma concentrations.

Similarly, severe renal dysfunction may increase the risk of toxic reactions due to altered elimination of the drug and its metabolites. This systemic risk is also noted for elderly, acutely ill, or debilitated patients, who may be less able to compensate for functional changes. No restrictions regarding food, alcohol, supplements, or mandatory timing separation rules are explicitly documented in the official prescribing information.

Advertisements

Mechanism of Action

How Marcain Heavy 0.5% Works


The mechanism of action is based on the reversible blockade of neuronal voltage-gated sodium channels ( Na^+ channels). Bupivacaine, the active compound, diffuses across the nerve cell membrane and binds to the intracellular hydrophobic pore of the channel. This interaction is use-dependent, targeting channels in their activated or inactivated states during impulse transmission. The molecular blockade prevents the essential influx of Na^+ ions required for depolarization, thereby suppressing the generation and propagation of the action potential along the spinal nerve axons.

This Na^+ channel blockade results in a phenomenon called differential blockade, where smaller, less myelinated sensory fibers (nociceptive signaling) are suppressed at lower concentrations than larger motor fibers. Furthermore, the solution’s hyperbaric nature, created by the glucose excipient, physically controls the drug’s distribution via gravity within the cerebrospinal fluid, supporting the localized application of the block to specific spinal segments. This suppression of nerve signal transmission constitutes the physiological consequence of the drug's mechanism.

Advertisements

Dosage and Administration Information

Marcain Heavy 0.5% (bupivacaine hydrochloride in dextrose injection) is a hyperbaric solution administered exclusively as a spinal (intrathecal) injection to produce regional anesthesia. This procedure involves a lumbar puncture to inject the solution into the subarachnoid space, typically performed by a clinician with specialized training and experience in a properly equipped setting.

Administration and Dosage

The drug is intended for single use only, and any remaining solution must be discarded. It must not be injected directly into the blood (intravascularly) or into inflamed or infected areas. The dosage is highly individualized, as it depends on factors such as the patient's physical status, age, the area and duration of anesthesia required, and the planned surgical procedure.

Indication (Surgical Procedure) Recommended Dose Volume Bupivacaine Dose Approximate Duration Injection Site Recommendation
Urological Surgery 1.5–3.0 mL 7.5–15 mg 2–3 hours L3–L4 intervertebral space
Lower Limb/Hip Surgery 2–4 mL 10–20 mg 2–3 hours L3–L4 intervertebral space
Lower Abdominal/Caesarean Section 2–4 mL 10–20 mg 45–60 minutes L3–L4 intervertebral space

Note: Dosage adjustments are typically necessary for elderly or debilitated patients, as well as those in the late stages of pregnancy, to mitigate risks of excessive spread or toxicity.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Marcain Heavy 0.5%

Research into Marcain Heavy 0.5% (Hyperbaric Bupivacaine) has centered on its use for regional anesthesia administered into the spine. Clinical evaluation mainly explores the speed of onset and duration of the numbing effect across specific types of surgical procedures.


Evidence for Use in Lower Body Surgical Procedures

Research for procedures like lower abdominal, urological, and limb surgeries involves Randomized Controlled Trials (RCTs) and regulatory clinical studies. These studies primarily monitor the time to onset and duration of the sensory and motor blocks, alongside measuring the total incidence of anesthesia failure (conversion to general anesthesia).

Findings describe patterns related to the effect's time-course; however, data are often insufficient to provide definitive insight into specific differences between this hyperbaric formulation and standard isobaric versions in non-obstetric settings.


Evidence for Use in Obstetrical Procedures (Caesarean Section)

For Caesarean sections, the evidence base is more extensive, including numerous Systematic Reviews and Meta-analyses. Studies monitored block quality, the requirement for supplemental analgesia, and the incidence of switching to general anesthesia. What is still uncertain is whether the hyperbaric formulation shows a difference in efficacy compared to other types of bupivacaine in preventing total anesthesia failure, as comparative evidence for this specific outcome is sometimes of limited methodological quality.


Long-Term Studies and Follow-Up

Clinical trials are designed to assess the anesthetic's function, meaning follow-up durations are naturally limited to the intraoperative and immediate postoperative phases. Consequently, long-term functional outcomes following the use of this specific spinal injection are not fully established in the available efficacy literature.


Evidence in Special Populations

Research has explored the medication's use in older adult patients to assess age-related differences in block characteristics. Additionally, specific clinical studies have been conducted in the pediatric population, including neonates and infants, to evaluate dose-response relationships and systemic exposure. The available data for pediatric patients are less voluminous compared to the adult populations, and findings for certain complex procedures remain uncertain.


What is Still Uncertain About Marcain Heavy 0.5%

The clinical research highlights areas where certainty remains low. Studies describe a degree of inherent unpredictability in the spread and effect duration of the spinal block, which may be related to individual patient anatomy or cerebrospinal fluid dynamics. Furthermore, comparative evidence that clarifies differences in critical failure rates between the hyperbaric and isobaric formulations for all indications is lacking or is subject to varying quality ratings across studies.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Marcain Heavy 0.5% (FAQ)

Q: What is the main difference between Marcain Heavy 0.5% and regular Marcain?

Official documentation describes Marcain Spinal 0.5% Heavy as a hyperbaric solution because it contains added glucose. This excipient makes the solution denser than cerebrospinal fluid (spinal fluid). Regular Marcain Spinal 0.5% is an isobaric solution, meaning its density is closer to that of the spinal fluid. The hyperbaric property allows the spread of the anesthetic to be controlled by gravity and the patient's physical position.


Q: Why is this drug referred to as 'heavy'?

The term 'Heavy' is a plain-language way of describing the medicine's hyperbaric quality. This hyperbaric feature means the solution is made denser (heavier) than the body's natural spinal fluid through the addition of glucose. This intentional increase in density ensures that the anesthetic’s spread within the spinal canal is precisely managed by gravity and the patient's position.


Q: How quickly does the numbing effect usually start?

According to official product information, the numbing (sensory) effect for spinal administration is typically very rapid. The effect often begins within one minute of injection. The time it takes to reach the full or maximum level of the anesthetic block is usually reached within 15 minutes in most cases.


Q: How long does the effect of Marcain Heavy 0.5% last?

The duration of the anesthetic effect depends on the dose administered and the surgical procedure being performed. Regulatory information indicates that the numbing effect typically lasts between 1.5 to 3 hours for lower abdominal, urological, and lower limb surgeries. For a Caesarean section, the duration is often shorter, around 45 to 60 minutes.


Q: Is it normal to feel a tingling sensation when the drug is injected?

Abnormal skin sensations, such as tingling or a 'pins and needles' feeling (paresthesia), are listed in official safety information as a Common side effect, meaning it may affect up to 1 in 10 people who receive the injection.


Q: Is it true that older adults might react differently to Marcain Heavy 0.5%?

Official documents note that older adults and patients in the late stages of pregnancy have an increased risk of a high or total spinal blockade. For this reason, the dose administered is often reduced for these populations. They also have a documented increased risk of experiencing low blood pressure (hypotension).


Q: What should I know about the feeling when the numbing starts to wear off?

The numbing effect of this medication is based on a reversible nerve block, meaning sensation is expected to return over time. As the anesthetic wears off, regulatory documents list temporary muscle weakness (paresis) as an Uncommon side effect, affecting up to 1 in 100 people.


Q: Does the drug have any known interactions with blood thinners?

Official prescribing information lists uncorrected coagulation disorders (severe bleeding or blood clotting problems) as a contraindication (a reason not to use the medicine). This is due to the risk of hemorrhage that can be associated with the spinal injection procedure itself, as described in regulatory documents.


Q: What level of pain relief can someone typically expect?

The general purpose of this specific preparation is to produce profound local anesthesia in a defined region of the body. This is intended to create controlled numbness and complete relief from sensation for the purpose of facilitating surgical and medical procedures.


Q: How long after the injection should I remain lying down?

The medicine is formulated to be controlled by gravity and the patient's position after injection. Official documentation confirms that the spread of the anesthetic in the spinal canal is directly influenced by the position of the patient and the time spent in that position immediately following the injection. The control of the anesthetic's spread and its effect is managed by the healthcare provider based on the patient’s position.


Q: What is the difference between an epidural and a spinal block using this medicine?

Marcain Spinal 0.5% Heavy is strictly designed for a spinal (intrathecal) block, which means the medicine is injected into the fluid around the spinal cord (subarachnoid space). An epidural block is a different procedure, often using other bupivacaine formulations, where the injection is placed into the epidural space, which is outside the fluid-filled sac surrounding the spinal cord.


Q: Does Marcain Heavy 0.5% have an effect on blood pressure?

A fall in blood pressure (hypotension) is listed in regulatory documents as a Very Common effect, affecting more than 1 in 10 people who receive a spinal block. This change in blood pressure is a known and expected physiological consequence of the sympathetic nerve blockade caused by the procedure.


Q: Does this medicine contain latex or preservatives?

According to official product information, the solution for injection is preservative-free and is intended for single use only. Official documents list the active substance (bupivacaine hydrochloride) and the excipients (glucose and water) but do not indicate the presence of latex.


Q: Is there any research that discusses the safety of Marcain Heavy 0.5% in pregnant women?

Official safety information classifies the general drug class (Bupivacaine) as having been used in a large number of women during pregnancy without an increase in malformations (TGA Category A). However, the dose is generally reduced in the late stages of pregnancy due to an increased risk of high spinal blockade.


Q: What kind of studies have been done on the long-term safety of this drug?

Clinical trials for this anesthetic are designed to assess its function during and immediately after a procedure. Consequently, follow-up durations are limited to the intraoperative and immediate postoperative phases. The official efficacy literature does not fully establish information on long-term functional outcomes following the use of this specific spinal injection.


Q: Is Marcain Heavy 0.5% suitable for use in children?

Regulatory information states that use of this product for spinal administration is not recommended for patients younger than 12 years. This is due to a lack of established safety and efficacy data for this type of anesthetic block in that specific pediatric population.


Q: Can Marcain Heavy 0.5% be used for pain relief after surgery?

This medicine is primarily indicated for producing local or regional anesthesia to facilitate surgical procedures. However, the long-acting nature of the drug, which is typical for bupivacaine, may provide an extended period of analgesia (pain relief) that persists after the primary numbing sensation begins to wear off.


Q: Are there foods or drinks to avoid when using this medicine?

The official prescribing information does not explicitly document any restrictions or mandatory timing separation rules regarding food or drinks in relation to the medicine itself.


Q: Does Marcain Heavy 0.5% cross the placental barrier?

Official safety information confirms that local anesthetics of this type can rapidly cross the placenta when used for regional block procedures. This is a documented consideration when the medicine is administered to patients during childbirth.


Q: What does 'hyperbaric solution' mean in simple terms?

A hyperbaric solution simply means the medicine is formulated to be heavier (denser) than the body's spinal fluid due to the intentional addition of glucose. This key physical characteristic allows the anesthetic's spread within the spinal canal to be precisely managed by gravity and the patient’s position.


Q: Is it normal to have a headache after receiving this injection?

A specific type of head pain called a Postdural Puncture Headache is listed in official safety information as a Common side effect. This means the headache may affect up to 1 in 10 people who receive this type of spinal injection.


Q: Can Marcain Heavy 0.5% affect my ability to drive after the procedure?

Official prescribing information states that, even without signs of toxicity, local anesthetics may have a very mild effect on mental function and coordination. The medication may temporarily impair a person’s locomotion and alertness, which are necessary for driving or operating machinery.


Q: What is the risk of the numbing not working?

Clinical studies for this medication monitor the total incidence of anesthesia failure, which means the block did not provide adequate pain relief. Research highlights that there is a degree of inherent unpredictability in the spread and effect duration of the spinal block, which is why close monitoring is required during the procedure.


Q: Why is the concentration exactly 0.5%?

The 0.5% concentration is one of the approved concentrations of bupivacaine that has been thoroughly studied in clinical trials. This concentration is officially indicated for the specific surgical and obstetrical procedures for which spinal anesthesia is used.


Q: What are the signs of too much medicine in the body (systemic toxicity)?

Regulatory documents list early warning signs of potential systemic toxicity, which can occur if the medicine is absorbed too rapidly. These signs may include feeling restless, anxious, lightheaded, or having a metallic taste. Other signs can include numbness or tingling around the mouth and lips, and tinnitus (ringing in the ears).


Q: How is the potency of Marcain Heavy 0.5% measured or compared?

Marcain Heavy 0.5% is pharmacologically classified as a long-acting local anesthetic. The effect is typically measured and compared in clinical studies by assessing the speed of onset and the duration of the sensory (numbing) and motor (muscle block) effects achieved.


Q: What are the signs that a person should seek immediate medical attention after the injection?

Official safety information highlights serious adverse reactions that require immediate medical attention, including signs of severe systemic allergic reactions (anaphylactic shock), severe breathing difficulty (respiratory depression), or sudden cardiac arrest. These severe signs are defined in regulatory documents as requiring immediate medical intervention by the administering healthcare team.

Advertisements

How should Marcain Heavy 0.5% be stored and disposed of?

Marcain Spinal 0.5% Heavy (bupivacaine hydrochloride in dextrose injection) must be stored and handled according to strict regulatory guidelines to maintain its integrity.

Scope Element Official Regulatory Statement
Storage Temperature Store at temperatures not exceeding 25 C.
Environmental Control The product must not be refrigerated or frozen.
Light Protection Keep the ampoules in the outer carton to protect from light.
Stability/Handling The solution is for single use only and must be used immediately after opening.
Disposal Any unused medicinal product or waste material must be disposed of in accordance with local requirements.
Child Safety Keep out of the sight and reach of children.

Regulatory labeling emphasizes the need for controlled room temperature storage and protection from freezing. Since the medicine is for single use, any portion remaining in the ampoule after initial use must be discarded immediately, following proper waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Marcain Heavy 0.5% found in:

A-Z Index: